ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.163,29
0,94%
S&P 500
5.157,49
0,58%
Dow Jones
38.728,58
0,14%
Euro vs US Dollar
1,0779
0,20%
Bitcoin
63.256,43
-1,16%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Acadia Pharmaceuticals Inc (ACAD)

  7. Acadia Pharmaceuticals Inc (ACAD) News

ACAD

Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ACAD
DatumZeitQuelleÜberschriftSymbolFirma
29/04/202422h16Business WireAcadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling ScholarshipNASDAQ:ACADAcadia Pharmaceuticals Inc
24/04/202422h05Business WireAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
22/04/202415h04Business WireAcadia Pharmaceuticals annonce que la présentation de drogue nouvelle pour la trofinetide dans le traitement du syndrome de Rett a été acceptée pour dépôt et évaluation prioritaire par Santé CanadaNASDAQ:ACADAcadia Pharmaceuticals Inc
22/04/202415h04Business WireAcadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health CanadaNASDAQ:ACADAcadia Pharmaceuticals Inc
19/04/202422h05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
17/04/202422h05Business WireAcadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual MeetingNASDAQ:ACADAcadia Pharmaceuticals Inc
02/04/202422h05Business WireAcadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and DevelopmentNASDAQ:ACADAcadia Pharmaceuticals Inc
01/04/202422h05Business WireAcadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
15/03/202421h05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
13/03/202421h05Business WireAcadia Pharmaceuticals to Participate in the UBS Virtual CNS DayNASDAQ:ACADAcadia Pharmaceuticals Inc
12/03/202412h21IH Market NewsOracle Soars 13% With Exceptional Growth and Boosts Nvidia Shares With Collaboration Announcement, and MoreNASDAQ:ACADAcadia Pharmaceuticals Inc
11/03/202421h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
11/03/202421h05Business WireAcadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of SchizophreniaNASDAQ:ACADAcadia Pharmaceuticals Inc
29/02/202415h05Business WireAcadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
28/02/202400h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
28/02/202400h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
28/02/202400h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
28/02/202400h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
27/02/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
27/02/202422h05Business WireAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
21/02/202422h05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
14/02/202413h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ACADAcadia Pharmaceuticals Inc
13/02/202422h05Business WireAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
08/02/202423h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
08/02/202423h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
31/01/202403h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
31/01/202402h48Business WireAcadia Announces Additions to Executive TeamNASDAQ:ACADAcadia Pharmaceuticals Inc
26/01/202423h25Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACADAcadia Pharmaceuticals Inc
19/01/202422h05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
18/01/202422h05Business WireAcadia Announces the Passing of Former President Srdjan (Serge) StankovicNASDAQ:ACADAcadia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACAD

Kürzlich von Ihnen besucht

TG
BAS
BASF
DBI
DAX
DAX
AMEX
XLV
Health Care Select Sector
FX
EURGBP
Euro vs Sterling
TG
DTE
Deutsche Telekom
COIN
BTCUSD
Bitcoin
NASDAQ
AAPL
Apple
CCOM
US100
US Tech 100
NYSE
MCD
McDonalds
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MRK
Merck
NYSE
XOM
Exxon Mobil
DBI
MDAX
MDAX
NYSE
DIS
Walt Disney
TG
BAYN
Bayer
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten